SS-31 (Elamipretide) Research Peptide

Yes. Every batch of SS-31 (Elamipretide) is tested by an independent third-party laboratory using HPLC and MS-UPLC, confirming purity and mass identity before the batch is released. Pure Peptides does not test its own material.

Yes. The Certificate of Analysis for the batch currently in stock can be viewed and downloaded directly on this page, before you place an order. Each certificate states the batch number, the measured purity, and the date of analysis, and can be verified independently with the issuing laboratory using the report number it carries.

It means SS-31 (Elamipretide) is supplied for in-vitro laboratory research and for no other purpose, and must not be administered to humans or animals. SS-31 (elamipretide) is legal to purchase in the United States for in vitro and non-clinical laboratory research, and is not a scheduled substance under the Controlled Substances Act. Elamipretide is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorisation.

SS-31 (Elamipretide) ships from US stock with cold-chain packaging and full tracking; orders placed before noon EST on business days are typically dispatched the same business day. On arrival, store the lyophilized powder at -20°C or below, dry and protected from light.

SS-31, elamipretide, Bendavia, MTP-131 and Ocuvia are all names for one compound. SS-31 is the laboratory designation used in the preclinical mechanism work. Elamipretide is the international non-proprietary name and is what every clinical trial used. Bendavia and MTP-131 were development names, and PubChem treats them as synonyms rather than separate entries. Searching only "SS-31" will return the mechanism papers and miss the trials. The Published Research tab states which name each cited study used.

Mixed, and the larger and better-controlled the trial, the less it found. A single four-hour infusion in people with reduced heart pumping reduced ventricular volumes at the highest dose; a later trial giving it daily for four weeks found no change in the same measurement. In Barth syndrome, the randomized half of a trial missed both primary endpoints and the open-label half that followed reported improvements. In primary mitochondrial myopathy, a 218-person phase 3 trial missed both primary endpoints. Each of these is set out with its numbers on the Published Research tab.